Pharmaceuticals - Community Register

  

Community list of not active medicinal products for human use


EXPIRED  

Product information

Invented name: Clopidogrel Teva Generics B.V.
Auth. number : EU/1/10/650
INN : Clopidogrel
ATC: Anatomical main group: B - Blood and blood forming organs
Therapeutic subgroup: B01 - Antithrombotic agents
Pharmacological subgroup: B01A - Antithrombotic agents
Chemical subgroup: B01AC - Platelet aggregation inhibitors excluding Heparin
Chemical substance: B01AC04 - Clopidogrel
(See WHO ATC Index)
Indication: Clopidogrel is indicated in:
  • Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
  • Adult patients suffering from acute coronary syndrome:
    • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
    • ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Marketing Authorisation Holder: Teva Generics B.V.
Computerweg 10, NL-3542 DR Utrecht, Nederland

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
04/11/2010 Centralised - Authorisation EMEA/H/C/2254 (2010)7621 of 28/10/2010
02/05/2011 Centralised - Variation EMEA/H/C/2254/IB/1
Updated with Decision(2011)8847 of 24/11/2011
27/07/2011 Centralised - Variation EMEA/H/C/2254/IB/2/G
Updated with Decision(2011)8847 of 24/11/2011
20/09/2011 Centralised - Variation EMEA/H/C/2254/IB/4
Updated with Decision(2011)8847 of 24/11/2011
29/11/2011 Centralised - Variation (2011)8847 of 24/11/2011
20/04/2012 Centralised - Variation EMEA/H/C/2254/IB/7
Updated with Decision(2012)7868 of 29/10/2012
31/10/2012 Centralised - Variation (2012)7868 of 29/10/2012
21/10/2013 Centralised - Variation EMEA/H/C/2254/IB/10
05/11/2013 Centralised - Withdrawal
07/01/2014 Centralised - Variation EMEA/H/C/2254/II/11